BMEA

Biomea Fusion, Inc.

15.98 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Biomea Fusion, Inc. stock is down -6.39% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
05 Feb 19:16 17 Jan, 2025 15.00 CALL 153 401
06 Feb 14:35 16 Jan, 2026 20.00 CALL 50 14
06 Feb 15:26 15 Mar, 2024 20.00 CALL 100 8509
08 Feb 15:25 17 Jan, 2025 20.00 CALL 42 1077
09 Feb 18:11 19 Apr, 2024 17.50 CALL 100 218
12 Feb 18:58 17 Jan, 2025 15.00 CALL 141 527
13 Feb 20:32 15 Mar, 2024 17.50 CALL 100 781
15 Feb 18:57 15 Mar, 2024 15.00 PUT 300 6600
21 Feb 20:59 15 Mar, 2024 15.00 PUT 100 7082
22 Feb 15:22 15 Mar, 2024 22.50 CALL 250 1426

About Biomea Fusion, Inc.

Biomea Fusion, Inc. focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.